Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated